Central Asset Investments & Management Holdings HK Ltd Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Central Asset Investments & Management Holdings HK Ltd purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 14,200 shares of the company’s stock, valued at approximately $96,000.

A number of other institutional investors and hedge funds have also modified their holdings of RXRX. IFP Advisors Inc grew its holdings in Recursion Pharmaceuticals by 170.4% in the fourth quarter. IFP Advisors Inc now owns 11,831 shares of the company’s stock valued at $80,000 after purchasing an additional 7,455 shares during the last quarter. Colonial River Investments LLC purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $68,000. Handelsbanken Fonder AB grew its position in shares of Recursion Pharmaceuticals by 5.9% in the fourth quarter. Handelsbanken Fonder AB now owns 73,600 shares of the company’s stock valued at $498,000 after purchasing an additional 4,100 shares during the last quarter. Private Advisor Group LLC raised its position in shares of Recursion Pharmaceuticals by 103.8% during the 4th quarter. Private Advisor Group LLC now owns 31,427 shares of the company’s stock worth $212,000 after purchasing an additional 16,008 shares during the last quarter. Finally, Global Retirement Partners LLC lifted its stake in Recursion Pharmaceuticals by 31.5% in the 4th quarter. Global Retirement Partners LLC now owns 31,297 shares of the company’s stock valued at $212,000 after buying an additional 7,500 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RXRX. KeyCorp dropped their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th.

Recursion Pharmaceuticals Stock Up 2.5 %

RXRX opened at $8.34 on Thursday. The stock has a market capitalization of $3.26 billion, a price-to-earnings ratio of -5.45 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The business has a 50-day moving average of $7.66 and a two-hundred day moving average of $7.06.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.